Cargando…

Effect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: A meta-analysis

This study evaluates the impact of the use of antibiotics on the effectiveness of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer (NSCLC). A literature search was conducted in various electronic databases to identify studies, which evaluated the impact of antibiotic use...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huo, Geng-wei, Zuo, Ran, Song, Ying, Chen, Wei-dong, Chen, Wen-ming, Chong, Dao-qun, Zhang, Hong-mei, Jia, Sha-sha, Chen, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	De Gruyter 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114955/ https://www.ncbi.nlm.nih.gov/pubmed/34013044 http://dx.doi.org/10.1515/med-2021-0272

Ejemplares similares

The incidence of gastrointestinal adverse events in patients with advanced non-small cell lung cancer (NSCLC) treated with PD-1 inhibitors: a meta-analysis
por: Huo, Geng-Wei, et al.
Publicado: (2021)

Efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis
por: Zhang, Qi, et al.
Publicado: (2020)

Nivolumab in Metastatic Non–Small Cell Lung Cancer
por: Deel, Andrea
Publicado: (2016)

Efficacy and safety of nivolumab for metastatic biliary tract cancer
por: Gou, Miaomiao, et al.
Publicado: (2019)

A meta-analysis of nivolumab for the treatment of advanced non-small-cell lung cancer
por: Chen, Shuo, et al.
Publicado: (2018)

Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial
por: Tamiya, Motohiro, et al.
Publicado: (2018)

Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis
por: Yang, Yi, et al.
Publicado: (2020)

Efficacy and Safety of Nivolumab for Advanced Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
por: Zhang, Siqi, et al.
Publicado: (2022)

Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety
por: Hida, Toyoaki
Publicado: (2018)

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
por: Janjigian, Yelena Y., et al.
Publicado: (2018)

The efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: a meta-analysis of prospective clinical trials
por: Huang, Jiaxing, et al.
Publicado: (2016)

Subset analysis of the safety and efficacy of nivolumab in elderly patients with metastatic melanoma
por: Freeman, Morganna, et al.
Publicado: (2015)

Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study
por: Iinuma, Koji, et al.
Publicado: (2021)

Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer
por: Lv, Weize, et al.
Publicado: (2022)

Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer
por: Ang, Yvonne LE, et al.
Publicado: (2016)

Efficacy and Safety of Nivolumab in Patients with Advanced Non-small-cell Lung Cancer and Poor Performance Status
por: Katsura, Hideyuki, et al.
Publicado: (2019)

Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non‐small cell lung cancer
por: Hida, Toyoaki, et al.
Publicado: (2017)

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
por: Amin, Asim, et al.
Publicado: (2018)

Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients
por: Stoff, Ronen, et al.
Publicado: (2022)

Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC
por: Wang, Yang, et al.
Publicado: (2021)

Low-dose nivolumab in advanced hepatocellular carcinoma
por: Chen, Yen-Hao, et al.
Publicado: (2022)

The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials
por: Jin, Conghui, et al.
Publicado: (2016)

Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab
por: Ouaknine Krief, Julia, et al.
Publicado: (2019)

Bilateral uveitis associated with nivolumab therapy for metastatic non-small cell lung cancer
por: Dermarkarian, Christopher R., et al.
Publicado: (2020)

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
por: Amin, Asim, et al.
Publicado: (2019)

Efficacy of subsequent docetaxel +/− ramucirumab and S‐1 after nivolumab for patients with advanced non‐small cell lung cancer
por: Tamura, Nobumasa, et al.
Publicado: (2019)

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
por: Diab, Adi, et al.
Publicado: (2021)

Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer
por: Geier, Margaux, et al.
Publicado: (2020)

Concurrent use of nivolumab and radiotherapy for patients with metastatic non-small cell lung cancer and renal cell carcinoma with oligometastatic disease progression on nivolumab
por: Ansari, Jawaher, et al.
Publicado: (2021)

Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma
por: Niwa, Kazutomo, et al.
Publicado: (2020)

Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab
por: Noel, Johanna, et al.
Publicado: (2022)

Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma
por: Homicsko, Krisztian, et al.
Publicado: (2022)

Metastatic Merkel cell carcinoma response to nivolumab
por: Walocko, Frances M., et al.
Publicado: (2016)

Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
por: Oro-Ayude, Marcos, et al.
Publicado: (2020)

Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China
por: Zhou, Dongchu, et al.
Publicado: (2022)

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
por: Vauchier, Charles, et al.
Publicado: (2022)

Circulating tumor cells prior to initial treatment is an important prognostic factor of survival in non-small cell lung cancer: a meta-analysis and system review
por: Jiang, Sha-Sha, et al.
Publicado: (2019)

Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
por: Alonso-García, Miriam, et al.
Publicado: (2022)

Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence
por: Lim, Joline S. J., et al.
Publicado: (2016)

Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis
por: Cai, Qi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rt16c6rumri42duq71o3hgj21q